Earnings Call: Q1 2021

May 12, 2021

Earnings release

Greetings, and welcome to the EDAP TMS First Quarter 2021 Earnings Conference Call. At this time, all participants are in a listen only mode. A question and answer session will follow the formal presentation. As a reminder, this conference is being recorded. It is now my pleasure to introduce your host, Jeremy Feffer with Investor Relations. Thank you. Please go ahead. Thank you, Donna. Good morning, and thank you for joining us for the EDAP CMS Q1 2021 financial and operating results Call. On today's call, we will hear from Mark Uchsikowski, Chief Executive Officer and Chairman of the Board and Francois Dietsch, Chief Financial Officer. Before we begin, I would like to remind everyone that management's remarks today may contain forward looking statements, which include statements regarding the company's growth and expansion plans. Such statements are based on management's current expectations and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in such forward looking statements. Factors that may cause such a difference include, but are not limited to, those described in the company's filings with the Securities and Exchange Commission. I would now like to turn the call over to EDAP's Chairman and Chief Executive Officer, Mark Uchakowski. Mark? Thank you, Jeremy, and good morning, everyone. I will start by providing a brief operational update and then turn the call over to Francois Licht to review our financial performance. First, let me start by saying that we believe the Q1 of 2021 and subsequent period marks an important point in the growth trajectory of our business. Without question, the successful commercialization of any novel technology must be supported by present and timely investments. In April, we had the opportunity to raise substantial capital that will enable us to fully support our ongoing U. S. Focal One commercialization effort, while also advancing a key clinical program in endometriosis. This capital raise was strategically important for several reasons. First and foremost, our strengthened balance sheet now provides us the additional resources to fully engage multiple channels across the U. S. Healthcare market. In addition to investing further in market access and reimbursement, which I will discuss in a moment, these additional funds will allow us to attract top tier talent with vast expertise in driving adoption of innovative technologies such as Focal One. In addition, we are building out our U. S. Clinical marketing and sales organization so that we are well positioned in this most important market. With HIFU gaining broader acceptance as an effective and less invasive paradigm for the management of prostate cancer relative to surgical options, we will firmly establish ourselves as the leader and clearly at the right place at the right time. To that end, we will continue to invest in our U. S. Infrastructure And these activities will be complemented by the many top tier hospitals that have already adopted Focal One that are serving as important reference accounts for our company. Some of these include Mount Sinai, Cleveland Clinic, Ochsner Medical Center, UCSF and many others, and our pipeline continues to grow, notwithstanding restrictions on some sales and outreach activities resulting from the pandemic. While our strategic marketing efforts will clearly involve engaging leading KOLs, it's equally important that Focal One reaches a wide breadth of urology medical practices and the added resources provided from this funding will help us maximize the opportunity to develop these important relationships. Secondly, our recent financing was also a clear sign of investor confidence that our HIFU technology represents an important advancement in the management of prostate cancer. As we all know, clinical data generated from well controlled trials ultimately drive medical decision making over time. Without question, the capital we raised during the Q1 clearly reflects a recognition by the investment community that FOTO1 is becoming an important new treatment option for patients battling prostate cancer. Finally, I would also like to add that we truly appreciate the high quality healthcare focused investors that participated in this offering. It is gratifying to know that after spending so much time conducting due diligence on our technology and studying the competitive dynamics of our end market, these firms have placed their capital with us based upon the shared vision of bringing an important new innovation to the market. This financing also resulted in expanding research coverage, which we believe will help raise the awareness of our company and the significant unmet need that we are addressing. Of course, launching a new medical technology in the U. S. Healthcare market brings several challenges, not least of which is navigating a complex reimbursement third payer landscape. Changing long standing medical practices is never easy and while adding a superior technology, sufficient capital and a sizable marketing apparatus are all essential elements to a successful product launch. We also recognize that building productive relationships with private insurers and government entities like CMS are critical to establishing Focal One as an accepted mainstream provider. In early March, we announced increased partnerships with 2 of the leading reimbursement consultancies, MTP and Argenta Advisors. These partnerships are off to a strong start and we anticipate positive momentum on the reimbursement and market access front across key hospital networks and physician practices throughout the remainder of this year and beyond. Securing active reimbursement level and achieving the broad possible patient coverage for CopaOne remain top priorities for our company and these 2 strategic partnerships coupled with the previously announced establishment of a Category 1 TPC code and reimbursement physician performing ablation of malignant prostate tissue with hyphen in the U. S. Will help us drive further adoption and growth across the U. S. From a sales perspective, our combined Focal One ExactView offering continues to resonate with healthcare institutions as the only end to end urology suite available on the market today. Now I will provide a brief update on our hemophilia prerelease program. As noted during our last conference call, this Phase 2 study will enroll a total of 38 women across 5 major hospitals in France, who will be accessed over a 6 month follow-up period. Investigators will evaluate the safety and efficacy of HIFU polypathology. At the end of April, we opened a second trial in Angie France that has already successfully treated 2 patients. Across both trial sites, we have now treated a total of 19 patients. Enrollment is tracking closely with our internal expectations as we are pleased to be able to execute this study according to our original timeline. We believe the treatment of endometriosis could be greatly improved with application of place invasive processes and the use of HIFU technology could offer an important minimally invasive treatment option for these patients. We look forward to updating you on this important program throughout the year. Francois will cover the financials in a moment, but let me provide a few highlights from the Q1. I am happy to report that we generated 1st quarter total revenue of €10,300,000 or $12,400,000 which represents a strong growth of 35.4% year over year and a new Q1 record revenues for the company. We expanded our gross margin to 42.4%, an increase of 220 basis points as compared to 14.2% in the Q1 of 2020. Revenue growth and margin expansion led us to achieve a profitable quarter for the company, both on the operating and net income basis. Our high school revenues were down slightly versus the Q4 of 2020. This was a difficult comparison as we had a property audit from December, finding key accounts, a few of which we outlined in the press release on December 30. We also experienced some softness in high food treatment driven revenues in Q1, particularly in Europe, where the pandemic has hit especially hard. However, it is important to note that there is a natural light between treatment driven revenues and cases performed at hospitals by kids in both and use them over time. In the U. S. Particularly, we are pleased by the continued growth in the number of treatment performed in Q1. Most of our key academic centers have increased their HIFU treatment numbers as compared to Q1 of last year and also sequentially as compared to Q4 of 2020. This is in part driven by the adoption of the Category 1 CPT code since its official implementation in January of 2021, as well as the broadening awareness of HIFU as an important addition to the neurologist development guidance. Turning to our very strong cash position, we ended the Q1 with cash and cash equivalents of €24,400,000 or €28,600,000 as compared to €24,700,000 or $30,200,000 as of December 31, 2020. As noted earlier, subsequent to the end of the Q1, we completed another recent public offering of American Repository Shares that yielded gross proceeds of approximately $38,000,000 We have a strong balance sheet with which to advance our accelerated growth plan in the U. S. And elsewhere. And now our CFO, Francois Litch, will provide some details of our financial results. Francois? Thank you, Marc, and good morning, everyone. Please note that on figures except for percentages, are in euros. For conversion properties, our average euro dollar exchange rate was 1.1990 for the Q1 of 2021. Total revenue for the Q1 was €10,300,000 an increase of 35.4 percent versus €7,600,000 in Q1 2020, reaching a new record level for Q1. Total revenue in the HIFU business for the Q1 of 2021 was €1,800,000 a decline of 6.2 percent compared to €1,900,000 for the Q1 of 2020. The modest decline is driven primarily to the effect of the COVID pandemic, which continues to adversely impact positive volumes. Also we are not seeing a positive trend. Total revenue in the digital business for the Q1 of 2021 was €2,900,000 roughly flat compared to €2,900,000 for the Q1 of 2020. Total revenue in the distribution business for the Q1 of 2021 was €5,600,000, a 102.5% increase compared to €2,800,000 for the Q1 of 2020, thanks to the exact imaging and laser cell development. Gross profit for the Q1 of 2021 was €4,400,000 compared to €3,100,000 for the year ago period. Gross profit margin and net sales was 42.4% in the Q1 of 2021 compared to 40.2% in the year ago period. The increase in gross profit year over year was due to the higher sales effect on fixed costs. Operating expenses were €4,100,000 for the Q1 of 2021 compared to €4,500,000 for the same period in 2020. Operating profit for the Q1 of 2021 was €200,000 compared to an operating loss of €1,500,000 in the Q1 of 2020. Net income for the Q1 of 2021 was €800,000 or 0 point 0 $3 per share diluted share, taking into account the €200,000 of financial income linked to the U. S. Paycheck Protection Program for VMS as compared to a net loss of €1,300,000 or €0.04 per diluted share in the year ago period. We ended the Q1 with cash and cash equivalents of €24,400,000 or €28,600,000 as compared to €24,700,000 or €30,200,000 at the end of December 2020. Subsequent to the end of the Q1, we completed an underwriting public offering of American Depositary Shares that yield net proceeds of approximately US25.6 million dollars As a result, our pro form a cash currently stands at approximately US54 million dollars Our pro form a ADS share count stands at approximately 33,400,000 shares, including an increase of 4,150,000 ADS issued pursuant to the underwriting offering. I may now turn the call back to Mark. Thank you, Francois. Before turning the call back to the operator to start our question and answer session, I would like to impress upon our investors that we now have in place the essential ingredients necessary for an accelerating commercial rent. A clinical proven technology leading to better patient outcomes, a clear and consistent messaging into our distribution channel, a strengthened balance sheet capable of supporting our future growth and key strategic partners who are helping us secure effective reimbursement for our 401 procedures. Despite continued challenges from the pandemic, 2021 promises to be a year in which our company transforms the treatment of prostate cancer and longer term, we remain extremely confident in the potential of our HIFU technology to address multiple therapeutic opportunities. We will now open the call to your questions. Operator? Thank you. The floor is now open for questions. Our first question is coming from Jason Bednar of Piper Sandler. Please go ahead. Hello. I hope everyone is well. My first question, Mark, you mentioned growing demand with HIFU here in the quarter. Has the uptick in utilization continued thus far into the second quarter? And then can you talk about how new Focal One conversations have been going here just the last few months? Hey, Jason. Well, thank you. Thank you for joining. Yes, what I said is that the trend and the number of cases performed in the U. S. During Q1 has shown a significant growth as compared to last year Q1, but as well as Q4. So that's again, that shows some momentum in the adoption and in the recruitment of patients in our different machines that are again that have been bought by academic centers and mainly KOL sites. I didn't get the other part of the question, sorry. It was just on what time just how new Focal One conversations have been going here just the last few months, what basically what the funnel looks like from a demand perspective? Yes. And as I said, I mean, we continue to grow our pipeline of projects. And again, we continue to get more and more leads in our pipeline. So it's going pretty well. Okay, great. And then maybe a 2 part question on the investments that you're planning. Are you willing to talk about the pace and sizing of this deployment over the coming quarters? And then understanding you still need to make the investments, can you talk about any time then when we should expect to see returns from the investments and account for this in our models? Can you sorry, Jason, maybe the line is not too good, but I didn't get the first part of your question. Can you repeat that? Yes. I was just wondering if you could talk about the pace and sizing, how quick and how much we'll see as far as the investments go? Any kind of guidance or color there for the rest of the year? And then the second part of the question was kind of similar on the pace and sizing of when the returns might be showing up, whether that's how much of a lag should we be building in? I understand this won't come immediately. Should we be expecting a 3 to 6 month lag, 6 to 12 month lag on when these again the fruits of the investment start showing up? So, well, actually, as I said a few times, it's and still we are in the beginning of the year, the beginning of the budget cycle. So and within the context of the pandemic, still it's difficult to have a very clear visibility on the advancement of the different projects and needs that we have. So it will be difficult for me to clearly answer your first part of the question. Now for the second part, again, it's we work on building coverage and market acceptance. And as we discussed several times, this is something that takes a lot of time, though we expect to achieve milestones and increase covered lives at a significant pace. And as this grows, definitely the return on investment will start building. So one is linked to the other. And again, we will put in action, in execution all of our accelerated plans and actions in order to get into that as quick as possible and therefore generate returns as fast as possible as well. Okay. All right, understood. And then maybe just one last one for me. Mark, you mentioned some key wins on the reimbursement front. Could you expand on what these wins were and maybe again expectations on what further progress there might be on the reimbursement front from a coverage standpoint here for the remainder of 2021? It's all about coverage. Again, as I said, we got the CPT code implemented at the beginning of the year. Now we need to build coverage. We need to recruit, I mean, to get more covered lives. So this is the goal and these are the milestones. So again, the idea is to get as much MAX for the CMS part as possible, having automatic coverage and positive LCDs issues. And on the other hand, the idea is to get private payers starting to get into their policies the HIFU reimbursement. So this is the plan and these are the metrics. All right, understood. Thanks so much. Thanks, Jason. Thank you. Our next question is coming from Andrew D'Silva of B. Riley. Please go ahead. Hey, good morning. Thanks for taking my questions. Just a few quick ones for me to start. Could you start by just letting us know how many Focal 1, Alitherm, ESWL and ExactView systems were placed in the quarter. And while that info is being pulled, I'm just kind of curious why ExactView seems to be moving at a much stronger pace than even the HIFU segment. Can you just talk about maybe what's driving that relative to even VocaOne, which had its own reimbursement and is really a very, very complementary offering and both have a capital equipment need. So I was just very surprised by the product mix. Okay. Hello, Andy. Thanks for the question. So it's a long question. So I may ask you for to repeat the second part of the question. But as far as equipment sold, we got 6 liter filters, 5 X ACTU machines and we had no HIFU devices in the Q1 as we as the same as last year. And the rest location was what? Just really trying to understand why ExactView is progressing so quickly even relative to Focal One, particularly both since both capital equipment items and very complementary to one another. So I've just been very surprised by the over performance of ExactView, particularly in regard to HIFU. Yes. Actually, it's a good question though. The capital investment is significantly different in purchasing a Focal One or an exact view is like more than 3 times more expensive to buy a Focal One. So it's very different. The indication is different as well. I mean, the exact view is used to perform diagnostic of prostate cancer when Focal One is for the treatment. So these are 2 different things. Just to give you an idea in terms of number of equipments or markets, and again, the price is different, is significantly higher on Focal One. They are in the U. S, as I shared on a frequently basis, there are about 1,000,000 biopsies performed every year on the prostate. And typically, Xyteu addresses that market of diagnostics. When on prostate cancer, newly diagnosed cases, it's about 250,000 cases in the U. S. Every year. So it's a different type of market and the volume of equipment sold will be different between an ultrasound diagnostic tool and a surgical minimally invasive equipment tool. Even though, as you said, they are very complementary, but usually have much more diagnostic equipment in the field than treating equipment. That makes sense. And as it relates to Ablotherm versus Focal 1, is there a strategy with that system? And the reason I ask is I noticed that last or during the Q4, you actually placed a couple systems. So I wasn't sure if we should be thinking about Alitherm in any sort of material way going forward or if those are more one off situations? Yes. No, that's more punctual. And the important thing as well is that we don't manufacture ABLETRM anymore. And the ABLETRM machine we sold are usually secondhand or refurbished equipment. And in the case of the equipment we sold at the end of last year that were secondary machine, we did in the past some trading program for our other term users in the U. S. To upgrade to a Focal one. So they were buying a Focal one and we were trading in the other term. So for those that want to invest little money in getting into HIFU, 2nd hand megatherm are good opportunities. So it's really a punctual and opportunistic business. Okay. Okay, perfect. And last quarter, you referenced your partnership with MTP and Arjenta. I was just curious how things were progressing with commercial reimbursement and maybe let us know what initiatives we should be looking for next out of those partnerships? Yes, we started and actually we started we announced the increased partnership with those companies last time, but we started to work with them before. That's how we got the C code and then the CPT code. That's a long relationship that we've had. We increased the relationship now because we want to focus on coverage. And most of the initiatives is to really get started on speaking with private payers. And we actually already started to do some meeting with medical directors of private insurances. So we work on that. We also built our hotline to give support to our existing users so that they can claim the right way and properly with our support their cases and get those claim done and covered. So it's all about this kind of initiative. And as I said, as well as we now have completed the financing, we will increase further the action plan in helping our sites, in lobbying the payers and in building more coverage with those partners, but also with the key people that we're going to get into our team. Okay. But nothing should really materially deviate beyond what we previously talked about as far as the commercial coefficient multiplier being 1.5 to 3 times higher than that of Medicare, correct? Yes, we're not there yet, but that's ultimately when they decide to cover, they will use their usual multiples that can be viable from one to the other. Okay. And last question, just kind of getting a little more granular on what kind of investments we should be expecting from a U. S. Commercialization standpoint now that you've got the recent capital infusion. Could you maybe just discuss where you are today with your sales force and support of reps that are focused on U. S. Sales and maybe where you hope to be by the end of the year from a sales rep standpoint? And then if someone could just talk around what we should kind of think about OpEx looking like for the year, that would be helpful. Obviously, the Q1 was very well managed, particularly relative to the Q4 of last year. So any guidance or assistance there would be very useful. Thank you very much. Yes. Thanks for the question. Though I mean, I don't have yet the way and the name of the guys, but we're talking with a number of people. And again, the idea, like I said today, and I said that before as well, we really want to build and increase the company. We really want to bring and strengthen our clinical marketing and sales team. It's not only about sales people, it's also about, again, helping building the coverage by more marketing initiatives, by more clinical initiatives gathering the clinical data from our top tier academic centers that are already using the technology. So we will definitely before the end of the year grow significantly the company and again not only in the sales force, but would increase, but also in the marketing and clinical departments so that we have more actions and initiatives on that side as well. Okay. But just say today, do you expect it to be like 2 or 3 times bigger as far as the size of the sales force and marketing team and clinical teams domestically in aggregate? Yes. That will be again as much as possible. Now we have all the ingredients like I said to move forward and deliver and execute. Now it's all a question as well of opportunity. And again, the idea is not just to double or triple the sales force, the idea is to get the best guys. So I don't want to double my sales force with people that will not sell. I want to get the best salespeople and that's what we are building. So we're looking for speed, but we're also looking for quality. So the idea is a good compromise. And again, that's the difference between theoretical. So I can tell you we're going to double it in theory. But if I can find if I can triple it because I find the right guide, I will do. If I can just increase by 50% because I only find the right guide, 50% of increase, that's what I will do. So it's a compromise that's realized. It's a compromise between quality and speed. And again, our idea is to go the fastest way possible with the best quality of people and partners involved in our program so that we can achieve it successfully as quick as possible. Very good point. Thank you very much. Best of luck. Thanks, Andy. Looking forward to watching progress. Thank you. Thank you. Our next question is coming from Frank Tackanan of Lake Street Capital Markets. Please go ahead. Hey, thanks for taking the questions. Wanted to start with ExactVu. Mark, could you update us on roughly speaking the overlap of sites with both ExactVUE and Focal 1? And then I wanted to kind of target the sites that do have an ExactVUE installed and how you view that opportunity to sell Focal 1 into? Yes, that's a good question. And again, the complement between the 2 technologies and devices is evident and the synergies as well. Again, as one is very dedicated to precisely and on a targeted way diagnose where prostate cancer is in the prostate. So that's the exact view. And then once you add that level of capability of diagnosing prostate cancer, then you want certainly to do some targeted and focal treatment. And that's where Focal One fits perfectly exact view. So again, that's really the way it has a good complement. And that's really the way they work perfectly together. On the second part of your question, it is true that the pipeline of projects or the installed base of ExactDuty, which is about 100 systems around the world now, certainly for those that don't have a focal one yet, the logical next step when you are able to do targeted diagnostics is to be able to do focal treatment or targeted treatment. So these are extremely good candidates to initiate a Focal 1 project. So that's I mean, indeed, all those existing exact new users are extremely good candidate and targets for building projects in Focal One in generating sales. Perfect. Thank you. And then next on endometriosis, I think this is kind of a little bit of a hidden gem here given all the attention given to HIFU for prostate cancer. Could you just update us, I heard the comments about the new site enrolling a couple of patients, but could you just update us on expected milestones over the next 12 months to 24 months? And then if I remember correctly, I believe the Focal 1 is already the regulatory landscape for Focal 1 already has endometriosis in place. So you don't have to go through another regulatory process rather, it's more about generating data to support the use of the system and indication. Am I thinking about that correctly? Not really, not exactly. Focal 1 is approved for prostate, for prostate tissue relation or prostate cancer treatment depending on where you are in the world. But the device is the exact same in the investigation for the endometriosis program. Now the study that we're doing, the Phase 2 study and probably a Phase 3 study that we'll conduct after this one will be a key in the regulatory path towards C marking and then FDA clearance. So it's not yet approved or cleared for endometriosis treatment. As far as the milestones and the regulatory aspect is one of the milestones, ultimately, the milestones are to conclude recruitment on the Phase 2 study within the year. And hopefully, that will be also based on how the pandemic will impact on us. But so far, we're doing very well. As I said, we've done already half of the treatment. We've done 19 out of 38, and that goes pretty well. We opened the 2nd site. We will soon open other sites. As a reminder, we have five centers that are involved in the Nutri Centric study Phase 2. So the idea is to within this year to conclude the recruitment and treatment of patients. Then we have a follow-up of 6 months. So that gives you an idea of the next milestone, which is the end of the study. And then based on that, the idea would be to discuss with healthcare authorities to see if the data gathered during the Phase 2 studies are enough to get into a regulatory discussion or shall we need to get started on a Phase III, which will start in any case, just like you said to get some clinical data. So this is a little bit the program and the different milestones in front of us. Got it. That makes sense. And then last one for me, given the higher mix of distribution in the quarter and the expectation of HIFU trending back up through the end of the year, is it safe to assume we should expect gross margins to trend upward through the end of fiscal year 2021? Yes, it's a good assumption. Let me add it that this way. And as you know, HIFU contributes very positively to increasing the gross margin. So that's what we see. Perfect. Thanks for taking all my questions. Thanks, Frank. Thank you. Our next question is coming from Swayampakula Ramakanth of H. C. Wainwright. Please go ahead. Thank you. This is RK. Good afternoon, Mark. Hello, RK. Hi. Ablotherm and Focal One have been with some of the Tier 1 organizations for quite a long time, some of them probably starting from when you had the clinical program going on with some of these folks. At this point, do you think that you have exhausted all the leads within the Tier 1 institutions? And what learnings have you gotten from these from the experience from these folks that you can take to the next level now that you have the CPD code probably the discussions are a little bit easier to get to the Tier 2 institutions? Well, thank you, Ake, for the question. No, we have not yet covered all the Tier 1 institutions. As we discussed several times, there are 5,000 hospitals in the U. S. And about 1500 to 1700 of them are having a urology department dealing with prostate. The Tier 1 hospitals are about 10% of those, so it's about 150 to 170 hospitals in the country that are considered academic centers or reference centers for the management of prostate cancer. As you know, we have about 15 focal 1 and we had a few additional labotherms. So we are far from saturating the Tier 1 and we have a lot of potential in front of us. And most of our current leads in the pipeline that as I said is continuing to increase are within that category of Tier 1 hospitals. So we still have a lot to expand in there. And again, the more covered lives we have, the easier it will be to convert those leads into sales. And as you say, ultimately, when we expand further the coverage and the adoption of the technology, then we start including Tier 2 hospitals. So we still have a long way and great potential in front of us. Great, great. And as you stated, it looks like the coverage is becoming the key now in terms of trying to increase adoption. So towards that end, obviously, you have picked up you have been working with these consultancies for a while now. So in this in the road to getting complete reimbursement or more of the reimbursement wins. What are the potential next steps now that you have the CPD code? And also just trying to figure out, does that help you to help some of these centers to increase the procedure rate? And because last time we were talking, there were some of these folks were still trying to figure out how to use the code and how to get through the paperwork. How far are they into that and just highlight to us a little bit about what are the ways that you as an organization are trying to help these folks increase their procedure volume now? So basically that's a little bit what I said before today. First, we need to the next steps are getting more covered lives and that's through getting LCDs from the MACs on CMS Medicare patient side and that's by getting more and more private insurance, including HIFU in their policies, either treatment in their policies. So these are the next milestones to recruit these payers and have them covering the technology on another incremental basis. What we are doing and like you said, when you have a new technology, when you have a new code, it's always a challenge and always needs help, support and education even on big reference centers to have them claiming properly. And that's what I just explained a few minutes ago in explaining some of the actions that we are now putting on place and increasing in terms of support. And that's part of it is the hotline that we've created to support all of our users in getting their claim done the proper way and the fast way so that they can get coverage, they can get reimbursement. So these are all the initiatives. And again, that's part of what I said before. Now that we have concluded that financing, we will increase further the clinical marketing and sales initiatives so that we will generate more leads, more sales, but we will also help our users and current and future to increase the number of treatments and number of procedures performed on our equipment. It's all about volume here. Thanks. Thanks for taking my questions. Thank you, Ate. Thank you. At this time, I would like to turn the floor back over to management for any additional or closing comments. Thank you, operator, and thank you everyone for joining us today. We will update you on all our programs and initiatives as we move forward, and we'll be happy to have you on the call for the Q2 earning calls in summer. Thank you very much. You all have a good day.